


Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.



| | | | | | |
|---|---|--------------------------|------------------|------------------------|-----------|
| Substitute for form 1449/PTO | | Complete if Known | | | |
| INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | Application Number | 09/976,468 | | |
| | | Filing Date | 10/12/2001 | | |
| | | First Named Inventor | DiMartino et al. | | |
| | | Art Unit | 1623 | | |
| | | Examiner Name | Lewis | | |
| Sheet | 1 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | APPELBAUM, F., "Allogeneic Stem-Cell Transplantation for Hematological Malignancies", 1 ed. <i>Medical Management of Hematological Malignant Diseases</i> , ed. E. Freireich. Vol. 1. 1998, New York: Marceil Dekker. 572. | |
| | | ARMITAGE, J., "Bone Marrow Transplantation", <i>The New England Journal of Medicine</i> , (1994). 330(12):827-838. | |
| | | BAGASRA, O. et al., "Adenosine-deaminase-associated immunodeficiency. I. Differential sensitivities of lymphocyte subpopulations exposed to 2-deoxycoformycin in vivo", <i>Clinical & Experimental Immunology</i> , (1992), 88(3):383-388. | |
| | | BEATTY, P. et al., "Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies", <i>Transplantation</i> , (February 1991), 51(2):443-447. | |
| | | BOLANOS-MEADE, J. et al., "Pentostatin in steroid-refractory acute graft-versus-host disease", <i>Journal of Clinical Oncology</i> , (April 20, 2005), 23(12):2661-2668. | |
| | | CATOVSKY, D. "Clinical experience with 2'-deoxycoformycin", <i>Hematology & Cell Therapy</i> , (1996), 38(S2):S103-S107. | |
| | | CATOVSKY, D. et al., "Long term results with 2'-deoxycoformycin in hairy cell leukemia", <i>Leukemia & Lymphoma</i> , (1994). 14(S1):109-113. | |
| | | CUMMINGS, F.J. et al., "Phase II trial of pentostatin in refractory lymphomas and cutaneous T-cell disease", <i>Journal of Clinical Oncology</i> , (April 1991), 9(4):565-571. | |
| ✓ | | EPSTEIN J. et al., "Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2'-deoxycoformycin", <i>Experimental Hematology</i> , 1986. 14(9): p. 845-849. | |
| PL | | FERRARA, J., "Cytokine Inhibitors and Graft-versus-Host Disease", <i>Annals New York Academy of Sciences</i> , (December 29, 1995), 770:227-236. | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner signature | | Date Considered | 10-4-05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | DiMartino et al. |
| | | | | Art Unit | 1623 |
| | | | | Examiner Name | Lewis |
| Sheet | 2 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|-----------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | FOSS, F.M. et al., "Phase II study of pentostatin and intermittent high-dose recombinant interferon alfa-2a in advanced mycosis fungoides/Sezary syndrome", <i>Journal of Clinical Oncology</i> , (December 1987), 10(12):1907-1913. | |
| | | GIBLETT, E.R. et al., "Adenosine-deaminase Deficiency in Two Patients With Severely Impaired Immunity", <i>Lancet</i> , (November 18, 1972). 2:1067-1069. | |
| | | GREVER, M. et al., "Optimal treatment for untreated patients with hairy cell leukemia?", 1996 ASCO Abstract Form, <i>Journal of Clinical Oncology</i> , (October 1995), 13(10):2677-2679. | |
| | | GREVER M. et al., "Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study", Comment in: <i>J Clin Oncol.</i> , (October 13, 1995), 13(10):2677-2679. | |
| | | GREVER, M. et al., "Low dose doxycoformycin in lymphoid malignancy", <i>Journal Clinical Oncology</i> , (September 1985), 3(9):1196-1201. | |
| | | GREVER, M.R. et al., "Clinical Pharmacokinetics of 2-Deoxycoformycin in Renal Impairment", <i>Proceedings of ASCO</i> , (1993), 12(361):140. | |
| | | GREVER, M.R. et al., "Inhibition of K and NK Lymphocyte Cytotoxicity by an Inhibitor of Adenosine Deaminase and Deoxyadenosine", <i>The Journal Of Immunology</i> , (December 1982), 129(6):365-369. | |
| | | KHOURI, I.F. et al., "Allogeneic blood or marrow transplantation for chronic lymphocytic leukemia: timing of transplantation and potential effect of fludarabine on acute graft-versus-host disease", <i>British Journal of Hematology</i> , (May 1997), 97(2):466-473. | |
| | | KOLB, H-J et al., "Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients", <i>Blood</i> , (September 1, 1995), 86(5):2041-2050. | |
| V | | KRAUT, E.H. et al., "Immunosuppressive effects of pentostatin", <i>Journal of Clinical Oncology</i> , (1990), 8(5):848-855. | |
| PL | | KRAUT, E.H. et al., "Low-Dose Deoxycoformycin in the Treatment of Hairy Cell Leukemia", <i>Blood</i> , (1986). 68(5):1119-1122. | |

| | | | |
|--------------------|--|-----------------|---------|
| Examiner signature | | Date Considered | 10-4-05 |
|--------------------|--|-----------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|-------|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | DiMartino et al. |
| | | | | Art Unit | 1623 |
| Examiner Name | Lewis | | | | |
| Sheet | 3 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | KRAUT, E.H. et al., "Pentostatin in the Treatment of Advanced Hairy Cell Leukemia", <i>Journal of Clinical Oncology</i> , (1989), 7(2):168-172. | |
| | | LEE, S.J., "New approaches for preventing and treating chronic graft-versus-host disease", <i>Blood</i> , (June 2005), 105(11):4200-4206. | |
| | | MARGOLIS, J. et al., ASH (1999), <i>Blood</i> , 94 # 10 Suppl 1 abstract 4878. | |
| | | MARGOLIS, J. et al., ASH (2000), <i>Blood</i> 96 #11 abstract 1723. | |
| | | MARTIN, P.J. et al., "A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment", <i>Blood</i> , (October 15, 1990), 76(8):1464-1472. | |
| | | MARTIN, P.J. et al., "A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment", <i>Blood</i> , (April 15, 1991), 77(8):1821-1828. | |
| | | MONFARDINI, S. et al., "Pentostatin (2'-deoxycorformycin, dCF) in patients with low-grade (B-T-cell) and intermediate- and high-grade (T-cell) malignant lymphomas: phase II study of the EORTC Early Clinical Trials Group", <i>Oncology</i> , 1996. 53(2):163-168. | |
| | | NASH, R.A. et al., "Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate", <i>Blood</i> , (October 1, 1992), 80(7):1838-1845. | |
| | | OR, R. et al., "Fludarabine monophosphate reduces the incidence and severity of graft-versus-host disease in a murine model of bone marrow transplantation", <i>Blood</i> , (July 1, 1997), 90(1):471-476. | |
| ✓ | | PRZEPIORKA, D. et al., "Consensus Conference on Acute GVHD Grading", <i>Bone Marrow Transplantation</i> , (June 1995), 15(6):825-828. | |
| PL | | RUERS, T.J.M. et al., "Inhibition of Lymphocyte-Specific Enzymes: A Promising Approach for Selective Immunosuppression", <i>Transplantation Proceedings</i> , (February 1987), 19(1):1287-1289. | |

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner signature |  | Date Considered | 10-4-05 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | DiMartino et al. |
| | | | | Art Unit | 1623 |
| | | | | Examiner Name | Lewis |
| Sheet | 4 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | SAVEN, A. et al., "Newer purine analogues for the treatment of hairy-cell leukemia", <i>New England Journal of Medicine</i> , (March 10, 1994). 330(10):691-697. | |
| I | | SEYMOUR, J.F. et al., "Response duration and recovery of CD4+ lymphocytes following deoxycoformycin in interferon-alpha-resistant hairy cell leukemia: 7-year follow-up", <i>Leukemia</i> , (1997), 11(1):42-47. | |
| I | | STEIS, R.G. et al., "Kinetics of recovery of CD4+ T cells in peripheral blood of deoxycoformycin-treated patients", <i>Journal of the National Cancer Institute</i> , (November 20, 1991), 83(22):1678-1679. | |
| ↓ | | URBA, W.J. et al., "Deoxycoformycin-Induced Immunosuppression in Patients With Hairy Cell Leukemia", <i>Blood</i> , (January 1989), 73(1):38-46. | |
| PL | | VOGELSANG, G. et al., "Graft-Versus-Host Disease: New Directions for a Persistent Problem", <i>Blood</i> , (October 1, 1994), 84(7):2061-2067. | |
| | | | |
| | | | |
| | | | |
| | | | |


| | | | |
|-----------------------|---|--------------------|---------|
| Examiner signature |  | Date Considered | 10-4-05 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | DiMartino et al. |
| | | | | Art Unit | 1623 |
| | | | | Examiner Name | Lewis |
| Sheet | 1 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | ABE, Y. et al., "Eradication of virus-infected T-cells in a case of adult T-cell leukemia/lymphoma by nonmyeloblastic peripheral blood stem cell transplantation with conditioning consisting of low-dose total body irradiation and pentostatin", Case Report, <i>International Journal of Hematology</i> , (July 2002), 76(1):91-93 | |
| | | ALCINDOR, T. et al., "Engraftment and immunologic effects a novel less myeloablative allogeneic transplant conditioning regimen of continuous infusion pentostatin, photopheresis, and low dose TBI", <i>PROC. Blood</i> , (2000), 96(11):327a, abst 5160. | |
| | | BAYER, R. et al., "Pentostatin based non-myeloablative conditioning regimen in patients with high-risk hematologic malignancy", <i>Proc of ASH</i> , (2000), 96(11):327, abst 5163. | |
| | | BOCIEK, G.R. et al., "Nonmyeloablative allogeneic stem cell transplantation (NST) for lymphoid malignancies using pentostatin/low-dose total body irradiation, <i>BB&MT</i> , (February 2004), 10(2), Supplement 1, page 27. | |
| | | CHAN, G. et al., "Decreased acute and chronic graft versus host disease with early full donor engraftment following a pentostatin-based preparative regimen for allogeneic bone marrow transplant in high-risk patients", <i>Proc Blood</i> , (2001), 98(11):383a, abst 1612. | |
| | | CHAN, G.W. et al., "Age is not associated with adverse outcomes following pentostatin-based preparative regimen for allogeneic bone marrow transplant", <i>Proc Blood</i> , (2001), 98(11):313b, abst 5011. | |
| | | CHAN, G.W. et al., "Even coagulase negative staphylococcus infections following reduced intensity transplantation are associated with increased transplant complications and poorer overall survival", <i>BB&MT</i> , (February 2004), 10(2), Supplement 1, page 11. | |
| | | CHAN, G.W. et al., "Extracorporeal photopheresis, pentostatin and total body irradiation reduced intensity transplantation in relapsed or refractory AML patients: evidence for early graft versus tumor effect with less GVHD", <i>Blood</i> , (November 16, 2003), 102(11), abst 3265. | |
| PL | | CHAN, G.W. et al., "Grade 2-4 acute graft-versus-host disease and extensive chronic graft-versus-host disease are associated with significantly decreased survival following reduced intensity allogeneic stem cell transplantation", <i>Blood</i> , (November 16, 2004), abst 1246. | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner signature | | Date Considered | 10-4-05 |
|-----------------------|--|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.


This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|-------|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | DiMartino et al. |
| | | | | Art Unit | 1623 |
| Examiner Name | Lewis | | | | |
| Sheet | 2 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|---|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | CHAN, G.W. et al., "MDS patients undergoing a novel reduced intensity allogeneic bone marrow transplant achieves complete remission with less transplant toxicity and graft versus host disease", <i>Proc. ASH</i> , (2002), abst 2450. | |
| | | CHAN, G.W. et al., "Persistence of host dendritic cells after transplantation is associated with graft-versus-host disease", (2003), 9:170-176. | |
| | | CHAN, G.W. et al., "Reduced-intensity transplantation for patients with myelodysplastic syndrome achieves durable remission with less graft-versus-host disease", <i>Biology of Blood and Marrow Transplantation</i> , (2003), 9:753-759. | |
| | | CHAN, G.W. et al., "Targeting host antigen-presenting cells pre-transplant reduces graft versus host disease", <i>BB&MT</i> , (2002), 8(2). | |
| | | CHIN, K.M. et al., "Favorable outcomes in matched unrelated donor allogeneic stem cell transplantation using a pentostatin/extracorporeal photopheresis based reduced intensity conditioning regimen", <i>Blood</i> , (November 16, 2003), 102(11), abst 1758. | |
| | | EPSTEIN, J. et al., "Prevention of graft-versus-host disease in allogeneic bone marrow transplantation by pretreatment with 2'-deoxycoryformycin", <i>Exp. Hematol.</i> , (1986), 14:845-849. | |
| | | FOSS, F. et al., "Novel pentostatin/extracorporeal photopheresis based allogeneic conditioning regimen for high risk non-Hogkin's lymphoma", <i>Annals of Oncology</i> , Vol. 13, Supp. 2, page 167, Abst 597. | |
| | | FOSS, F. et al., "Novel pentostatin/extracorporeal photopheresis reduced intensity conditioning regimen: results in relapsed/refractory NHL", <i>Proc. ASH</i> , (2002), abst 413. | |
| | | LIU, D. et al., "Graft-versus-lymphoma effect yields high percentage of durable complete remission in high risk patients following mini-transplantation with MAP (mitoxantrone, ARA-C, and pentostatin) regimen", <i>BB&MT</i> , (February 2004), 10(2), Supplement 1, page 35. | |
| | PL | | MILLER, K., "Reduced intensity allogeneic transplants", <i>Cancer Investigation</i> , (November 2002), Vol. 21, Supp. 1, pages 97-99. |

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner signature |  | Date Considered | 10-4-05 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|--|-------|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | DiMartino et al. |
| | | | | Art Unit | 1623 |
| Examiner Name | Lewis | | | | |
| Sheet | 3 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PK | | MILLER, K.B. et al., "Allotransplants: a novel reduced intensity regimen", <i>Cancer Investigation</i> , (November 2000), Vol. 20, Supp. 1, abst 82. | |
| | | MILLER, K.B. et al., "Reduced intensity conditioning regimens – a novel reduced intensity regimen for allogeneic hematopoietic stem cell transplantation associated with a reduced incidence of graft-versus-host disease", <i>Bone Marrow Transplantation</i> , (2004), 33:881-889. | |
| | | PAVLETIC, S.Z. et al., "Immunological effects of pentostatin in a minimally myelosuppressive regimen for allogeneic stem cell transplantation", <i>Proc. ASH</i> , (2002), abst 2446. | |
| | | PAVLETIC, S.Z. et al., "Immunomodulatory effects of pentostatin in a regimen for non-myeloablative stem cell transplantation", 3 rd International Workshop on iwNST held on January 18-21, 2002 in Captiva Island, FL, 1 page. | |
| | | PAVLETIC, S.Z. et al., "Lymphodepleting effects and safety of pentostatin for nonmyeloablative allogeneic stem-cell transplantation", <i>Brief Communications, Transplantation</i> , (September 15, 2003), 76(5):877-881. | |
| | | "Pentostatin effective as preparative regimen for kidney transplant", <i>Expert Review of Anticancer Therapy</i> , (2001), 1(4):508. | |
| | | RAO, R. et al., "Cytomegalovirus reactivation and relapse following allogeneic stem cell transplantation using a reduced intensity conditioning regimen", <i>Blood</i> , (November 16, 2004), 104(11), abst 5104. | |
| | | ROBERTS, T.F. et al., "A novel preparative regimen associated with reduced morbidity and mortality following allogeneic bone marrow transplant", <i>PROC. Blood</i> , (2000), 96(11):781a, abst 3378. | |
| | | ROBERTS, T.F. et al., "Outcome of 48 patients undergoing allogeneic bone marrow transplant with a reduced intensity preparative regimen of photopheresis, continuous infusion pentostatin and reduced dose TBI", <i>Journal of the American Society for Blood and Marrow Transplantation</i> , (2002), 8(2). | |
| PK | | RUERS, T.J. et al., "Complete suppression of skin allograft rejection in rats treated with continuous infusion of 2'-deoxycytosine", <i>Transplantation</i> , (1985), 40(2):137-142. | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner signature | | Date Considered | 10-4-05 |
|-----------------------|--|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary) | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | DiMartino et al. |
| | | | | Art Unit | 1623 |
| | | | | Examiner Name | Lewis |
| Sheet | 4 | of | 4 | Attorney Docket Number | 12636.219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|--|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | SANDMAIER, B.M. et al., "Conversion of low donor chimerism following nonmyeloablative conditioning for hematopoietic cell transplantation (HCT) using pentostatin and donor lymphocyte infusion (DLI)", <i>Blood</i> , (November 16, 2004), 104(11), abst 186. | |
| | | SCHILLER, G.J. et al., "Letter to the editor re allogeneic transplantation after nonmyelosuppressive conditioning—the effect of single-agent pentostatin", <i>BB&MT</i>, 10:576-577. | |
| PL | | SCHILLER, G.J. et al., "Transplantation of allogeneic peripheral blood progenitor cells after non-myelosuppressive preparative conditioning-A phase I/II trial of single-agent pentostatin as an innovative preparative regimen for allogeneic transplantation for kidney cancer", <i>Proc of ASH</i> , (2001), 98(11):184a, abst 773. | |
| PL | | SCHWARTZ, J.E. et al., "Pentostatin and cyclosporine, a new regimen for the prevention of acute graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation", <i>BB&MT</i> , (February 2004), 10(2), Supplement 1, page 50. | |
| PL | | SCHWARTZ, J.E. et al., "Pentostatin and cyclosporine for prevention of acute graft-versus-host disease after allogeneic peripheral blood progenitor cell transplantation", <i>Blood</i> , (November 16, 2003), 102(11), abst 5524. | |
| | | | |
| | | | |
| | | | |
| | | | |

| | | | |
|-----------------------|---|--------------------|---------|
| Examiner signature |  | Date Considered | 10-4-05 |
|-----------------------|---|--------------------|---------|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|-------------------|
| Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 09/976,468 |
| | | | | Filing Date | 10/12/2001 |
| | | | | First Named Inventor | Jorge DiMartino |
| | | | | Art Unit | 1623 |
| | | | | Examiner Name | Lewis, Patrick T. |
| Sheet | 1 | of | 1 | Attorney Docket Number | 12636-219 |

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| PL | | ARAI, S. et al., "Management of graft-versus-host disease", <i>Blood Reviews</i> (2000) 14:190-204 | |
| | | DE LIMA, M., "GVHD Prophylaxis With Tacrolimus, Mini-methotrexate, and Pentostatin: A Phase I/II Study", Revitalization of Pentostatin: A New Approach To The Management of GVHD and Allogeneic Transplants. Satellite Symposium at the 2004 Tandem BMT meetings. February 15, 2004; Orlando, Florida. | |
| | | DE LIMA, M. et al., "Pentostatin, Tacrolimus, and "Mini"-Methotrexate for Graft-Versus-Host Disease (GVHD) Prophylaxis: A Phase I/II Controlled, Randomized Study", <i>Blood</i> , (November 16, 2004), 104(11), abst 727. | |
| | | FOSS, F. et al., "Reduced-Intensity Conditioning for Allogeneic Transplantation", Revitalization of Pentostatin: A New Approach To The Management of GVHD and Allogeneic Transplants. Satellite Symposium at the 2004 Tandem BMT meetings. February 15, 2004; Orlando, Florida. | |
| | | HIGMAN, M. et al., "Pentostatin - Pharmacology, immunology, and clinical effects in graft-versus-host disease", <i>Expert Opinion</i> , (2004) 5(12): 2605-2613 | |
| | | JACOBSON, D. et al., "Novel Pharmacotherapeutic Approaches to Prevention and Treatment of GVHD", <i>Drugs</i> 2002; 62(6): 879-889 | |
| | | JACOBSON, D. et al., "Pentostatin: Efficacy in Refractory Chronic GVHD in Children", <i>Blood</i> , (November 16, 2004), 104(11), abst 2249. | |
| PL | | SANDMAIER, B. et al., "Nonmyeloablative Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies", Revitalization of Pentostatin: A New Approach To The Management of GVHD and Allogeneic Transplants. Satellite Symposium at the 2004 Tandem BMT meetings. February 15, 2004; Orlando, Florida. | |

| | | | |
|-----------------------|--|--------------------|---------|
| Examiner signature | | Date Considered | 10-4-05 |
|-----------------------|--|--------------------|---------|

*EXAMINER: Initial reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.